Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001649553-25-000046
Filing Date
2025-02-10
Accepted
2025-02-10 11:07:33
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9463
2 LIMITED POWER OF ATTORNEY anvs-sc13_exi.pdf EX-24 70124
3 JOINT FILING AGREEMENT anvs-sc13g_exii.pdf EX-99 184482
  Complete submission text file 0001649553-25-000046.txt   362316
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Subject) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91306 | Film No.: 25604388
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8080
CVI Investments, Inc. (Filed by) CIK: 0001649553 (see all company filings)

EIN.: 981253664 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G